#United Kingdom #Piramal Pharma #Morpeth #Solution

Piramal Pharma Solutions Celebrates 20 Years of Excellence

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), has proudly marked its 20th anniversary at its Morpeth facility in the UK with the acquisition of a state-of-the-art Korsch X3 tablet press. This significant installation underscores the site's expertise and commitment to advancing drug product manufacturing technology and enhancing patient care.

The new Korsch X3 tablet press is custom-built to cater to the unique needs of the Morpeth facility, equipped with full Band 5 containment. This feature allows for the safe manufacture of high-potency drug products, thereby positioning Morpeth to effectively respond to the growing demand for complex therapeutic solutions.

Peter DeYoung, CEO of Piramal Global Pharma, emphasized the importance of this milestone, stating, "By expanding Morpeth's capacity to manufacture tablets containing Band 5 HPAPIs, the Korsch X3 strengthens our ability to serve patients in therapeutic areas where high potency materials are essential, such as hormonals made in a dedicated hormone manufacturing facility."

The Korsch X3 is complemented by a specialized DryCon containment kit, enhancing the site’s efficiency in producing life-saving therapies. Its design includes features such as dual customized turrets that enable the production of larger tablets and improve operational efficiency. Additionally, the press integrates a state-of-the-art containment infeed system that minimizes exposure risks, ensuring a safer working environment for the staff.

This installation arrives on the heels of the commissioning of a smaller Korsch XM12 Single Layer/Bilayer press, which laid a solid foundation for adopting advanced tablet press technology at the site. As market demands for late phase and commercial products grow, the need for versatile production capabilities has become increasingly important. The Korsch X3 fits this requirement perfectly, allowing for a broader range of formulations and the high-throughput manufacturing of tablets.

Inclusive of dual-side glove ports and a misting system designed to mitigate dust, the Korsch X3 ensures worker safety during operations and changeovers, effectively addressing the risks linked to handling high-toxicity drugs. The team at Morpeth has also received thorough training from Korsch to confidently operate the new press.

Celebrating two decades of commitment to pharmaceutical manufacturing excellence, the Korsch X3 acquisition not only marks a significant technological advancement for Morpeth but also lays the groundwork for future innovations in the field. This forward-thinking approach is indicative of Piramal's ongoing dedication to patient-centric solutions.

The Morpeth facility, a key player in Piramal Pharma Solutions’ global network, has continuously evolved to meet the challenges and demands of the pharmaceutical industry. With an impressive portfolio of services ranging from clinical trial supplies to the development of highly potent APIs and biologics, Piramal remains at the forefront of pharmaceutical innovation.

As the Morpeth site celebrates its achievements, the installation of the Korsch X3 tablet press serves as a powerful symbol of its sustained investment in state-of-the-art technologies, and its unwavering commitment to enhancing patient outcomes with high-quality, safe, and effective drug products. The company is excited about the future and looks forward to continuing its legacy of improving lives through scientific advancement at Morpeth and beyond.

About Piramal Pharma Solutions: Piramal Pharma Solutions (PPS) operates with a globally integrated network of facilities offering end-to-end development and manufacturing services across the drug life cycle—from drug discovery to commercial supply. With a nuanced focus on advanced capabilities, the organization serves clients in North America, Europe, and Asia, maintaining a steadfast commitment to quality and innovation.

For more information, visit Piramal Pharma Solutions.